The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Screening for Liver Cancer Market Research Report 2024

Global Screening for Liver Cancer Market Research Report 2024

Publishing Date : Jul, 2023

License Type :
 

Report Code : 1763465

No of Pages : 97

Ask Your Query

Synopsis
Screening for Liver Cancer

Global Screening for Liver Cancer market is projected to reach US$ 14180 million in 2029, increasing from US$ 8717 million in 2022, with the CAGR of 7.2% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Screening for Liver Cancer market research.

Globally, liver cancer is one of the leading causes of cancer-related deaths. According to the American Cancer Society, the incidence of liver cancer has tripled since the 1980s, and the death rate has now doubled. In the United States, about 41,260 new cases are expected to be diagnosed, while about 30,520 deaths from liver cancer are expected, according to 2022 cancer statistics. The global prevalence of liver cancer and the continuous exposure of related populations to risk factors will rapidly drive the screening and diagnostics market.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Screening for Liver Cancer market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

By Company

  • Abbott Laboratories
  • Thermo Fisher Scientific, Inc.
  • Berry Oncology
  • New Horizon Health
  • BGI
  • GTH.O
  • Livzon
  • BNR.O
  • SingLera
  • Fujifilm Medical Systems U.S.A., Inc.
  • F. Hoffmann-La Roche Ltd.
  • Siemens Healthineers
  • BD
  • Illumina, Inc.
  • Epigenomics AG

Segment by Type

  • Hematology Test
  • Imaging Test

Segment by Application

  • Hospital
  • Clinic
  • Other

By Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia, Nordic Countries, Rest of Europe)
  • Asia-Pacific (China, Japan, South Korea,Southeast Asia, India, Australia, Rest of Asia)
  • Latin America (Mexico, Brazil, Rest of Latin America)
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)

The Screening for Liver Cancer report covers below items:

Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source

Index

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Screening for Liver Cancer Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Hematology Test
1.2.3 Imaging Test
1.3 Market by Application
1.3.1 Global Screening for Liver Cancer Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Screening for Liver Cancer Market Perspective (2018-2029)
2.2 Screening for Liver Cancer Growth Trends by Region
2.2.1 Global Screening for Liver Cancer Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Screening for Liver Cancer Historic Market Size by Region (2018-2023)
2.2.3 Screening for Liver Cancer Forecasted Market Size by Region (2024-2029)
2.3 Screening for Liver Cancer Market Dynamics
2.3.1 Screening for Liver Cancer Industry Trends
2.3.2 Screening for Liver Cancer Market Drivers
2.3.3 Screening for Liver Cancer Market Challenges
2.3.4 Screening for Liver Cancer Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Screening for Liver Cancer Players by Revenue
3.1.1 Global Top Screening for Liver Cancer Players by Revenue (2018-2023)
3.1.2 Global Screening for Liver Cancer Revenue Market Share by Players (2018-2023)
3.2 Global Screening for Liver Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Screening for Liver Cancer Revenue
3.4 Global Screening for Liver Cancer Market Concentration Ratio
3.4.1 Global Screening for Liver Cancer Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Screening for Liver Cancer Revenue in 2022
3.5 Screening for Liver Cancer Key Players Head office and Area Served
3.6 Key Players Screening for Liver Cancer Product Solution and Service
3.7 Date of Enter into Screening for Liver Cancer Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Screening for Liver Cancer Breakdown Data by Type
4.1 Global Screening for Liver Cancer Historic Market Size by Type (2018-2023)
4.2 Global Screening for Liver Cancer Forecasted Market Size by Type (2024-2029)
5 Screening for Liver Cancer Breakdown Data by Application
5.1 Global Screening for Liver Cancer Historic Market Size by Application (2018-2023)
5.2 Global Screening for Liver Cancer Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Screening for Liver Cancer Market Size (2018-2029)
6.2 North America Screening for Liver Cancer Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Screening for Liver Cancer Market Size by Country (2018-2023)
6.4 North America Screening for Liver Cancer Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Screening for Liver Cancer Market Size (2018-2029)
7.2 Europe Screening for Liver Cancer Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Screening for Liver Cancer Market Size by Country (2018-2023)
7.4 Europe Screening for Liver Cancer Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Screening for Liver Cancer Market Size (2018-2029)
8.2 Asia-Pacific Screening for Liver Cancer Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Screening for Liver Cancer Market Size by Region (2018-2023)
8.4 Asia-Pacific Screening for Liver Cancer Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Screening for Liver Cancer Market Size (2018-2029)
9.2 Latin America Screening for Liver Cancer Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Screening for Liver Cancer Market Size by Country (2018-2023)
9.4 Latin America Screening for Liver Cancer Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Screening for Liver Cancer Market Size (2018-2029)
10.2 Middle East & Africa Screening for Liver Cancer Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Screening for Liver Cancer Market Size by Country (2018-2023)
10.4 Middle East & Africa Screening for Liver Cancer Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Abbott Laboratories
11.1.1 Abbott Laboratories Company Detail
11.1.2 Abbott Laboratories Business Overview
11.1.3 Abbott Laboratories Screening for Liver Cancer Introduction
11.1.4 Abbott Laboratories Revenue in Screening for Liver Cancer Business (2018-2023)
11.1.5 Abbott Laboratories Recent Development
11.2 Thermo Fisher Scientific, Inc.
11.2.1 Thermo Fisher Scientific, Inc. Company Detail
11.2.2 Thermo Fisher Scientific, Inc. Business Overview
11.2.3 Thermo Fisher Scientific, Inc. Screening for Liver Cancer Introduction
11.2.4 Thermo Fisher Scientific, Inc. Revenue in Screening for Liver Cancer Business (2018-2023)
11.2.5 Thermo Fisher Scientific, Inc. Recent Development
11.3 Berry Oncology
11.3.1 Berry Oncology Company Detail
11.3.2 Berry Oncology Business Overview
11.3.3 Berry Oncology Screening for Liver Cancer Introduction
11.3.4 Berry Oncology Revenue in Screening for Liver Cancer Business (2018-2023)
11.3.5 Berry Oncology Recent Development
11.4 New Horizon Health
11.4.1 New Horizon Health Company Detail
11.4.2 New Horizon Health Business Overview
11.4.3 New Horizon Health Screening for Liver Cancer Introduction
11.4.4 New Horizon Health Revenue in Screening for Liver Cancer Business (2018-2023)
11.4.5 New Horizon Health Recent Development
11.5 BGI
11.5.1 BGI Company Detail
11.5.2 BGI Business Overview
11.5.3 BGI Screening for Liver Cancer Introduction
11.5.4 BGI Revenue in Screening for Liver Cancer Business (2018-2023)
11.5.5 BGI Recent Development
11.6 GTH.O
11.6.1 GTH.O Company Detail
11.6.2 GTH.O Business Overview
11.6.3 GTH.O Screening for Liver Cancer Introduction
11.6.4 GTH.O Revenue in Screening for Liver Cancer Business (2018-2023)
11.6.5 GTH.O Recent Development
11.7 Livzon
11.7.1 Livzon Company Detail
11.7.2 Livzon Business Overview
11.7.3 Livzon Screening for Liver Cancer Introduction
11.7.4 Livzon Revenue in Screening for Liver Cancer Business (2018-2023)
11.7.5 Livzon Recent Development
11.8 BNR.O
11.8.1 BNR.O Company Detail
11.8.2 BNR.O Business Overview
11.8.3 BNR.O Screening for Liver Cancer Introduction
11.8.4 BNR.O Revenue in Screening for Liver Cancer Business (2018-2023)
11.8.5 BNR.O Recent Development
11.9 SingLera
11.9.1 SingLera Company Detail
11.9.2 SingLera Business Overview
11.9.3 SingLera Screening for Liver Cancer Introduction
11.9.4 SingLera Revenue in Screening for Liver Cancer Business (2018-2023)
11.9.5 SingLera Recent Development
11.10 Fujifilm Medical Systems U.S.A., Inc.
11.10.1 Fujifilm Medical Systems U.S.A., Inc. Company Detail
11.10.2 Fujifilm Medical Systems U.S.A., Inc. Business Overview
11.10.3 Fujifilm Medical Systems U.S.A., Inc. Screening for Liver Cancer Introduction
11.10.4 Fujifilm Medical Systems U.S.A., Inc. Revenue in Screening for Liver Cancer Business (2018-2023)
11.10.5 Fujifilm Medical Systems U.S.A., Inc. Recent Development
11.11 F. Hoffmann-La Roche Ltd.
11.11.1 F. Hoffmann-La Roche Ltd. Company Detail
11.11.2 F. Hoffmann-La Roche Ltd. Business Overview
11.11.3 F. Hoffmann-La Roche Ltd. Screening for Liver Cancer Introduction
11.11.4 F. Hoffmann-La Roche Ltd. Revenue in Screening for Liver Cancer Business (2018-2023)
11.11.5 F. Hoffmann-La Roche Ltd. Recent Development
11.12 Siemens Healthineers
11.12.1 Siemens Healthineers Company Detail
11.12.2 Siemens Healthineers Business Overview
11.12.3 Siemens Healthineers Screening for Liver Cancer Introduction
11.12.4 Siemens Healthineers Revenue in Screening for Liver Cancer Business (2018-2023)
11.12.5 Siemens Healthineers Recent Development
11.13 BD
11.13.1 BD Company Detail
11.13.2 BD Business Overview
11.13.3 BD Screening for Liver Cancer Introduction
11.13.4 BD Revenue in Screening for Liver Cancer Business (2018-2023)
11.13.5 BD Recent Development
11.14 Illumina, Inc.
11.14.1 Illumina, Inc. Company Detail
11.14.2 Illumina, Inc. Business Overview
11.14.3 Illumina, Inc. Screening for Liver Cancer Introduction
11.14.4 Illumina, Inc. Revenue in Screening for Liver Cancer Business (2018-2023)
11.14.5 Illumina, Inc. Recent Development
11.15 Epigenomics AG
11.15.1 Epigenomics AG Company Detail
11.15.2 Epigenomics AG Business Overview
11.15.3 Epigenomics AG Screening for Liver Cancer Introduction
11.15.4 Epigenomics AG Revenue in Screening for Liver Cancer Business (2018-2023)
11.15.5 Epigenomics AG Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock